Skip to main content

Published locations for Nivolumab plus ipilimumab boosts PFS in advanced NSCLC with high tumor mutational burden

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Nivolumab plus ipilimumab boosts PFS in advanced NSCLC with high tumor mutational burden

User login

  • Reset your password
  • /content/nivolumab-plus-ipilimumab-boosts-pfs-advanced-nsclc-high-tumor-mutational-burden
  • /oncologypractice/article/163645/lung-cancer/nivolumab-plus-ipilimumab-boosts-pfs-advanced-nsclc-high
  • /fedprac/avaho/article/163645/lung-cancer/nivolumab-plus-ipilimumab-boosts-pfs-advanced-nsclc-high
  • /hematology-oncology/article/163645/lung-cancer/nivolumab-plus-ipilimumab-boosts-pfs-advanced-nsclc